Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

SGMO

Sangamo Therapeutics Inc

Apr 26 • 12:53PM ET

0.5160

Dollar change +0.0130
Percentage change 2.59	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN VTWO VHT SCHA IWC PRFZ FESM

Index	RUT	P/E	-	EPS (ttm)	-1.46	Insider Own	10.07%	Shs Outstand	203.67M	Perf Week	0.89%
Market Cap	105.10M	Forward P/E	-	EPS next Y	-0.25	Insider Trans	0.00%	Shs Float	183.15M	Perf Month	-17.39%
Income	-257.83M	PEG	-	EPS next Q	-0.21	Inst Own	46.37%	Short Float	7.23%	Perf Quarter	21.85%
Sales	176.23M	P/S	0.60	EPS this Y	66.30%	Inst Trans	7.00%	Short Ratio	5.47	Perf Half Y	7.51%
Book/sh	0.47	P/B	1.11	EPS next Y	50.13%	ROA	-70.85%	Short Interest	13.25M	Perf Year	-67.95%
Cash/sh	0.40	P/C	1.30	EPS next 5Y	-	ROE	-136.48%	52W Range	0.29 - 1.78	Perf YTD	-5.02%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-15.96%	ROI	-221.50%	52W High	-71.01%	Beta	1.40
Dividend TTM	-	Quick Ratio	1.98	Sales past 5Y	17.84%	Gross Margin	88.52%	52W Low	77.28%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	1.98	EPS Y/Y TTM	-17.27%	Oper. Margin	-64.85%	RSI (14)	40.24	Volatility	11.29% 9.82%
Employees	405	Debt/Eq	0.46	Sales Y/Y TTM	58.34%	Profit Margin	-146.30%	Recom	1.88	Target Price	3.50
Option/Short	Yes / Yes	LT Debt/Eq	0.40	EPS Q/Q	-7.61%	Payout	-	Rel Volume	0.24	Prev Close	0.50
Sales Surprise	-74.81%	EPS Surprise	-32.66%	Sales Q/Q	-92.50%	Earnings	Mar 13 BMO	Avg Volume	2.42M	Price	0.52
SMA20	-6.02%	SMA50	-34.44%	SMA200	-27.81%	Trades		Volume	316,304	Change	2.59%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-03-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$6 → $2
Apr-28-23	Downgrade	BofA Securities	Neutral → Underperform	$5 → $1.50
Feb-27-23	Upgrade	Wedbush	Neutral → Outperform	$16
Jan-06-23	Downgrade	BofA Securities	Buy → Neutral	$8 → $5
Jun-13-22	Resumed	Wedbush	Neutral	$5
May-04-21	Initiated	RBC Capital Mkts	Outperform	$22
Jan-07-21	Resumed	Guggenheim	Neutral	$16
Jan-06-21	Initiated	Stifel	Hold	$16
Dec-16-20	Resumed	H.C. Wainwright	Buy	$25
Sep-08-20	Initiated	BofA Securities	Buy	$20
Jul-07-20	Initiated	SunTrust	Buy	$22
Aug-26-19	Initiated	H.C. Wainwright	Buy	$16
Nov-14-18	Downgrade	JP Morgan	Overweight → Neutral
Nov-09-18	Downgrade	Guggenheim	Buy → Neutral
Oct-10-18	Initiated	Guggenheim	Buy
Jun-20-18	Initiated	BofA/Merrill	Buy	$24
Nov-15-17	Upgrade	Piper Jaffray	Neutral → Overweight
Jun-22-17	Resumed	Jefferies	Buy	$17
Nov-01-16	Downgrade	Wedbush	Outperform → Neutral	$30 → $4
Oct-19-16	Downgrade	Piper Jaffray	Overweight → Neutral

Show Previous Ratings

Apr-22-24 04:35PM	Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (Business Wire)
Mar-22-24 08:05AM	Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering (Business Wire) -27.55%
Mar-14-24 07:23AM	Q4 2023 Sangamo Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-13-24 08:21AM	Sangamo: Q4 Earnings Snapshot (Associated Press Finance) -8.83%
08:05AM	Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
08:01AM	Loading…
08:01AM	Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs (Business Wire)
Mar-12-24 06:30PM	Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast (Business Wire)
Feb-12-24 08:05AM	Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease (Business Wire) +40.15%
Feb-05-24 06:01PM	Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile (Business Wire) +13.91%
Nov-03-23 05:03PM	Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 08:15AM	Sangamo to cut jobs again with planned business overhaul (BioPharma Dive) -22.14%
Nov-01-23 07:05PM	Sangamo Therapeutics Inc (SGMO) Announces Q3 2023 Financial Results and Strategic Update (GuruFocus.com) -6.25%
04:13PM	Sangamo: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results (Business Wire)
Oct-26-23 10:02AM	Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
04:15PM	Loading…
Oct-25-23 04:15PM	Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast (Business Wire)
Oct-24-23 02:01AM	Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) (Business Wire)
Sep-20-23 04:15PM	Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit (Business Wire)
Aug-25-23 01:38PM	Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases (InvestorPlace) -12.49%
Aug-08-23 05:30PM	Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:26PM	Sangamo: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results (Business Wire)
Aug-01-23 04:15PM	Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast (Business Wire)
Jul-20-23 08:05AM	Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing (Business Wire)
Jul-19-23 07:08AM	The past five years for Sangamo Therapeutics (NASDAQ:SGMO) investors has not been profitable (Simply Wall St.)
Jul-17-23 08:05AM	Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids (Business Wire)
Jun-29-23 08:05AM	Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease (Business Wire)
Jun-28-23 09:20AM	FDA Accepts Pfizer's (PFE) Hemophilia B Gene Therapy Filing (Zacks)
Jun-14-23 08:16AM	We're A Little Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Rate (Simply Wall St.)
May-22-23 08:05AM	Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease (Business Wire) +5.43%
07:04AM	Loading…
May-18-23 07:04AM	Industry Analysts Just Upgraded Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Forecasts By 52% (Simply Wall St.)
May-16-23 08:00AM	Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer (Business Wire)
May-02-23 04:30PM	Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (Business Wire) -9.27%
06:03AM	Analysts Just Made A Huge Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Forecasts (Simply Wall St.)
Apr-26-23 05:28PM	Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results (Business Wire)
Apr-25-23 02:39PM	Biogen shifts gene therapy focus as it builds $200M facility in RTP (American City Business Journals)
Apr-21-23 04:58AM	Strength Seen in Pharming Group N.V. Sponsored ADR (PHAR): Can Its 5.2% Jump Turn into More Strength? (Zacks)
Apr-19-23 04:15PM	Sangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast (Business Wire)
Apr-17-23 07:38AM	Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Shares Lagging The Industry But So Is The Business (Simply Wall St.) +5.45%
Apr-16-23 06:30AM	7 Sorry Pharma Stocks to Sell in April Before Its Too Late (InvestorPlace)
Mar-23-23 06:09AM	The Petri Dish: Takeda scores win from Nimbus licensing deal; Biogen exits partnership (American City Business Journals)
Mar-21-23 09:35AM	Sangamo (SGMO) Loses -37.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Mar-20-23 12:25PM	Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo (Benzinga)
Mar-10-23 09:35AM	Sangamo (SGMO) Loses -24.09% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Feb-25-23 08:26AM	In the wake of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) latest US$56m market cap drop, institutional owners may be forced to take severe actions (Simply Wall St.)
Feb-23-23 05:36PM	Sickle-cell gene therapy developer stops program, cuts half of staff (American City Business Journals)
11:57AM	Sangamo Therapeutics Shares Updated Data From Fabry Gene Therapy Study, Says It Shows Evidence Of Clinical Benefit (Benzinga)
Feb-22-23 05:25PM	Sangamo Therapeutics (SGMO) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
03:01PM	Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease (Business Wire)
09:35AM	Here's Why Sangamo (SGMO) is Poised for a Turnaround After Losing -17.68% in 4 Weeks (Zacks)
Feb-21-23 09:01AM	Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast (Business Wire) -7.49%
Feb-16-23 10:01AM	Sangamo Therapeutics (SGMO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-13-23 09:55AM	Here's Why Sangamo (SGMO) Looks Ripe for Bottom Fishing (Zacks)
Feb-10-23 11:01AM	Why Bionano Genomics, Pacific Biosciences of California, and Sangamo Therapeutics Stocks Crumbled This Week (Motley Fool)
Jan-30-23 07:10PM	7 CRISPR Stocks With the Best Long-Term Potential (InvestorPlace) -5.03%
Dec-06-22 06:02AM	Sangamo Therapeutics (NASDAQ:SGMO) investors are sitting on a loss of 78% if they invested five years ago (Simply Wall St.)
Nov-09-22 05:31AM	Sangamo Therapeutics Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-03-22 05:55PM	Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results (Business Wire)
Oct-27-22 04:15PM	Sangamo Therapeutics Announces Third Quarter 2022 Conference Call and Webcast (Business Wire)
Oct-14-22 09:49AM	10 Best Gene Editing Stocks To Buy (Insider Monkey)
Oct-12-22 08:55AM	Sangamo Touts Additional Positive Data For Fabry Gene Therapy Candidate (Benzinga)
03:01AM	Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated -Gal A Enzyme Activity in Nine Patients (Business Wire)
Sep-23-22 12:02PM	Pfizer Resumes Dosing In Phase 3 Hemophilia Gene Therapy Trial Six Months After FDA Lifts Clinical Hold (Benzinga)
Sep-18-22 09:11AM	Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measures (Simply Wall St.)
Aug-30-22 08:50AM	Sangamo's Fabry Disease Gene Therapy Continues To Show Encouraging Safety Profile (Benzinga)
06:00AM	Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated -gal A Enzyme Activity in Five Longest Treated Patients (Business Wire)
Aug-29-22 09:55AM	Does Sangamo (SGMO) Have the Potential to Rally 122% as Wall Street Analysts Expect? (Zacks)
Aug-12-22 09:55AM	Wall Street Analysts Predict a 106% Upside in Sangamo (SGMO): Here's What You Should Know (Zacks) +8.76%
Aug-04-22 05:45PM	Sangamo Therapeutics (SGMO) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results (Business Wire)
Jul-28-22 04:15PM	Sangamo Therapeutics Announces Second Quarter 2022 Conference Call and Webcast (Business Wire)
Jul-21-22 08:05AM	European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation (Business Wire)
Jul-18-22 09:21AM	Is Sangamo Therapeutics (NASDAQ:SGMO) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jun-07-22 08:55AM	Shareholders in Sangamo Therapeutics (NASDAQ:SGMO) are in the red if they invested a year ago (Simply Wall St.) +8.65%
Jun-01-22 04:30PM	Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences (Business Wire)
May-08-22 08:09AM	Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analysts Are Reducing Their Forecasts For This Year (Simply Wall St.)
May-05-22 05:45PM	Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -6.11%
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results (Business Wire)
May-04-22 06:35PM	Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-02-22 04:30PM	Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (Business Wire) +6.99%
Apr-28-22 04:15PM	Sangamo Therapeutics Announces First Quarter 2022 Conference Call and Webcast (Business Wire)
Apr-21-22 04:30PM	Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences (Business Wire) -6.67%
Apr-11-22 08:59AM	What Type Of Shareholders Make Up Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Registry? (Simply Wall St.) -5.10%
Mar-30-22 06:40AM	Strength Seen in Sangamo (SGMO): Can Its 9.6% Jump Turn into More Strength? (Zacks) -5.57%
Mar-29-22 08:05AM	Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation (Business Wire) +9.60%
Feb-28-22 05:00PM	Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences (Business Wire)
Feb-24-22 06:20PM	Sangamo Therapeutics (SGMO) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +6.13%
04:01PM	Sangamo Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights (Business Wire)
Feb-17-22 04:30PM	Sangamo Therapeutics Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast (Business Wire)
Feb-08-22 11:32AM	Here's Why We're Watching Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation (Simply Wall St.)
06:52AM	Sangamo Therapeutics Shares Updated Interim Data From Fabry Disease Gene Therapy Trial (Benzinga)
Feb-07-22 06:00PM	Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated -Gal A Enzyme Activity in Patients With Fabry Disease (Business Wire)
Jan-21-22 05:38PM	PrairieView Partners, LLC Buys iShares Short-Term National Muni Bond ETF, Avantis Core ... (GuruFocus.com)
Jan-13-22 01:38PM	McGuire Investment Group, LLC Buys SPDR Bloomberg 1-3 Month T-Bill ETF, WisdomTree Floating ... (GuruFocus.com)
Jan-06-22 08:00AM	Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo (Business Wire)
Jan-04-22 05:00PM	Sangamo Therapeutics Announces Participation at H.C. Wainwright BIOCONNECT Virtual Conference (Business Wire) -5.12%
Dec-20-21 05:29PM	BioMarin settles trade secrets 'misunderstanding' with former employee (American City Business Journals)
Dec-13-21 10:54AM	Pfizer (PFE) Gets Approval for New Eczema Drug in Europe (Zacks) -5.69%

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BIOGEN INC.	10% Owner	Sep 26 '23	Sale	0.50	6,000,000	3,000,000	17,652,466	Sep 28 05:30 PM

Open in Screener

VSTM

Verastem Inc

Apr 26 • 12:52PM ET

9.39

Dollar change +0.18
Percentage change 1.90	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF AVSC

Index	-	P/E	-	EPS (ttm)	-4.08	Insider Own	19.05%	Shs Outstand	25.28M	Perf Week	-4.57%
Market Cap	237.57M	Forward P/E	-	EPS next Y	-2.75	Insider Trans	-0.41%	Shs Float	20.48M	Perf Month	-20.56%
Income	-87.37M	PEG	-	EPS next Q	-1.03	Inst Own	47.88%	Short Float	3.94%	Perf Quarter	-18.49%
Sales	0.00M	P/S	-	EPS this Y	5.09%	Inst Trans	-	Short Ratio	5.59	Perf Half Y	42.06%
Book/sh	2.27	P/B	4.14	EPS next Y	26.95%	ROA	-71.39%	Short Interest	0.81M	Perf Year	109.28%
Cash/sh	5.46	P/C	1.72	EPS next 5Y	1.74%	ROE	-138.76%	52W Range	4.26 - 15.18	Perf YTD	15.36%
Dividend Est.	-	P/FCF	-	EPS past 5Y	24.76%	ROI	-73.33%	52W High	-38.14%	Beta	0.60
Dividend TTM	-	Quick Ratio	5.45	Sales past 5Y	-45.06%	Gross Margin	-	52W Low	120.42%	ATR (14)	0.59
Dividend Ex-Date	-	Current Ratio	5.45	EPS Y/Y TTM	11.24%	Oper. Margin	0.00%	RSI (14)	31.66	Volatility	4.91% 5.56%
Employees	73	Debt/Eq	0.53	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	28.79
Option/Short	Yes / Yes	LT Debt/Eq	0.52	EPS Q/Q	-3.51%	Payout	-	Rel Volume	0.15	Prev Close	9.22
Sales Surprise	-100.00%	EPS Surprise	-66.83%	Sales Q/Q	-	Earnings	Mar 14 AMC	Avg Volume	144.18K	Price	9.39
SMA20	-14.09%	SMA50	-18.66%	SMA200	-2.17%	Trades		Volume	12,002	Change	1.90%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-21-23	Resumed	BTIG Research	Buy	$27
Sep-27-23	Initiated	B. Riley Securities	Buy	$21
Jun-15-23	Upgrade	Mizuho	Neutral → Buy	$24 → $36
Sep-07-22	Resumed	Alliance Global Partners	Buy	$6
Apr-29-22	Resumed	Cantor Fitzgerald	Overweight	$6 → $5
Apr-14-22	Initiated	RBC Capital Mkts	Outperform	$5
Mar-09-22	Initiated	Truist	Buy	$6
Jul-01-21	Initiated	Alliance Global Partners	Buy	$6
May-24-21	Upgrade	BTIG Research	Neutral → Buy	$8
Jun-20-19	Downgrade	BTIG Research	Buy → Neutral
May-10-19	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-13-18	Initiated	BTIG Research	Buy	$17
May-02-18	Initiated	Seaport Global Securities	Buy	$14
Mar-08-18	Initiated	B. Riley FBR, Inc.	Buy	$15
Sep-07-17	Reiterated	H.C. Wainwright	Buy	$6.50 → $10
Apr-13-17	Initiated	Oppenheimer	Outperform
Mar-24-17	Reiterated	H.C. Wainwright	Buy	$5 → $6.50
Sep-29-15	Downgrade	Raymond James	Strong Buy → Outperform
Sep-29-15	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-29-15	Downgrade	Jefferies	Buy → Hold

Show Previous Ratings

Apr-18-24 04:05PM	Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer (Business Wire) -5.63%
Apr-09-24 07:00AM	GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting (PR Newswire)
Apr-04-24 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.43%
Mar-18-24 07:00AM	Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer (Business Wire)
Mar-14-24 09:54PM	VSTM Stock Earnings: Verastem Misses EPS for Q4 2023 (InvestorPlace)
04:53PM	Loading…
04:53PM	Verastem: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates (Business Wire)
Mar-11-24 07:30AM	Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Womens Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs (Business Wire)
Mar-05-24 05:27PM	Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
04:30PM	Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024 (Business Wire)
Feb-15-24 03:12AM	Andreas Halvorsen's Viking Global Investors LP Bolsters Position in Verastem Inc (GuruFocus.com)
Feb-07-24 05:02PM	Director Robert Gagnon Sells 9,204 Shares of Verastem Inc (VSTM) (GuruFocus.com)
07:15AM	3 Stocks That AI Predicts Will Deliver Triple-Digit Returns This Year: February 2024 (InvestorPlace)
Jan-29-24 07:00AM	Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers (Business Wire) +7.12%
Jan-22-24 08:15AM	Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy (Zacks)
04:00PM	Loading…
Jan-18-24 04:00PM	Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC) (Business Wire) -6.48%
Jan-11-24 07:00AM	Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference (Business Wire)
Jan-05-24 07:00AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-18-23 07:00AM	Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics (Business Wire)
Dec-13-23 09:08AM	3 Off-the-Beaten-Path Stocks Poised for Substantial Growth (InvestorPlace) +10.67%
07:00AM	Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
Dec-03-23 04:17PM	Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential (InvestorPlace)
Nov-22-23 12:00PM	All You Need to Know About Verastem (VSTM) Rating Upgrade to Buy (Zacks)
Nov-13-23 07:00AM	New Healthcare Professional Component of Lets Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach (Business Wire)
Nov-08-23 05:52PM	Verastem: Q3 Earnings Snapshot (Associated Press Finance)
04:12PM	Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
Nov-07-23 07:00AM	First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer (Business Wire) +6.65%
Nov-06-23 07:00AM	Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population (Business Wire)
Oct-26-23 04:05PM	Verastem Oncology Strengthens Executive Leadership Team with Key Appointments (Business Wire)
Oct-18-23 04:50PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
12:30PM	Loading…
Oct-14-23 12:30PM	Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer (Business Wire)
Oct-06-23 07:00AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-28-23 02:15PM	Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit (Business Wire) -5.13%
Sep-05-23 07:00AM	Verastem Oncology to Participate in Upcoming Investor Conferences (Business Wire)
Sep-04-23 01:23PM	3 Penny Stocks That Can Triple Your Money in the Next 12 Months (InvestorPlace)
Aug-28-23 07:00AM	Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers (Business Wire)
Aug-08-23 05:46PM	Verastem: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
Jul-11-23 07:00AM	Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer (Business Wire)
Jul-10-23 04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +9.50%
Jul-05-23 04:05PM	Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
Jun-16-23 05:00AM	Verastem Oncology Announces Pricing of $85.0 Million Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Jun-15-23 04:06PM	Verastem Stock Is Outperforming 92% Of The Market And It Just Surged (Investor's Business Daily) +16.09%
04:00PM	Verastem Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
May-31-23 09:11AM	Verastem Oncology Announces Reverse Stock Split (Business Wire)
May-25-23 05:05PM	Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib (Business Wire)
May-16-23 07:00AM	Verastem Oncology Appoints Karin Tollefson, PhD, to Board of Directors (Business Wire)
May-09-23 04:56PM	Verastem: Q1 Earnings Snapshot (AP Finance)
04:05PM	Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
May-02-23 07:45AM	Strong week for Verastem (NASDAQ:VSTM) shareholders doesn't alleviate pain of five-year loss (Simply Wall St.)
May-01-23 07:00AM	Verastem Oncology to Participate in Upcoming Investor Conferences (Business Wire) +12.65%
Apr-26-23 04:05PM	New Data from Interim Analysis of Verastem Oncologys RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual Meeting (Business Wire)
Apr-18-23 07:05AM	Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days (Business Wire)
Apr-06-23 05:39PM	7 Very Undervalued Penny Stocks to Buy in April 2023 (InvestorPlace) -6.12%
04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-15-23 07:00AM	New Verastem Oncology Initiative, Lets Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer (Business Wire)
Mar-14-23 04:05PM	Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress (Business Wire)
Feb-02-23 07:00AM	Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers (Business Wire) +8.65%
Jan-30-23 12:00PM	Verastem (VSTM) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks) -5.80%
Jan-24-23 05:46PM	Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock (Business Wire)
05:45PM	Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
Jan-18-23 04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-11-23 06:24AM	individual investors who own 37% along with institutions invested in Verastem, Inc. (NASDAQ:VSTM) saw increase in their holdings value last week (Simply Wall St.) +11.00%
Dec-15-22 04:30PM	Verastem Oncology Appoints Rob Gagnon to Board of Directors (Business Wire) -5.00%
Nov-08-22 08:22AM	Verastem Third Quarter 2022 Earnings: US$0.092 loss per share (vs US$0.13 loss in 3Q 2021) (Simply Wall St.)
Nov-03-22 04:05PM	Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress (Business Wire)
Oct-20-22 07:00AM	Verastem Oncology Appoints Anil Kapur to Board of Directors (Business Wire)
Oct-07-22 04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.49%
Oct-04-22 07:00AM	Verastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate Updates (Business Wire) -34.60%
Sep-19-22 09:31AM	10 Long-Term Stocks to Buy During Recessions (Insider Monkey)
Aug-23-22 12:23PM	Investors five-year losses grow to 64% as the stock sheds US$34m this past week (Simply Wall St.)
Aug-08-22 07:00AM	Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress (Business Wire) +7.56%
Jul-27-22 11:40AM	Is Verastem (NASDAQ:VSTM) Using Too Much Debt? (Simply Wall St.)
Jul-07-22 07:00AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.93%
Jun-27-22 11:17AM	What You Need To Know About Verastem, Inc.'s (NASDAQ:VSTM) Investor Composition (Simply Wall St.)
Jun-07-22 02:26PM	RBC Says Verastem Interim Analysis In Ovarian Cancer Reinforces Enthusiasm (Benzinga) +11.07%
Jun-06-22 07:00AM	Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 ± Defactinib in Low-Grade Serous Ovarian Cancer (Business Wire) -8.27%
May-19-22 06:00PM	7 Cheap Biotech Stocks to Buy Now (InvestorPlace) +5.13%
May-18-22 08:45AM	Verastem Oncology Awarded Pancreatic Cancer Action Networks First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer (Business Wire)
May-09-22 04:05PM	Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress (Business Wire) -9.52%
08:25AM	Precision BioSciences (DTIL) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
Apr-04-22 04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.99%
Mar-28-22 01:46PM	Verastem Announces $150M Debt Financing To Support VS-6766, Defactinib Development (Benzinga) +10.92%
07:05AM	Verastem Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress (Business Wire)
07:00AM	Verastem Oncology Provides Financial Update to Support Development of VS-6766 and Defactinib in RAS Pathway-Driven Tumors (Business Wire)
Mar-24-22 07:05AM	Verastem Oncology Names Preeminent Oncology Researcher Channing Der, PhD, to its Scientific Advisory Board (Business Wire)
Mar-01-22 07:52AM	Mirati (MRTX) Q4 Earnings and Sales Fall Short of Estimates (Zacks)
Feb-22-22 05:00AM	Verastem (NASDAQ:VSTM) investors are sitting on a loss of 62% if they invested three years ago (Simply Wall St.)
Feb-03-22 05:38PM	Kalos Management, Inc. Buys Vale SA, Sells Consensus Cloud Solutions Inc, Intuitive Surgical ... (GuruFocus.com) -7.59%
Jan-11-22 07:00AM	Verastem Oncology Outlines Key 2022 Strategic Priorities and Upcoming Catalysts for Advancing VS-6766 as a Backbone of Therapy for RAS Pathway-Driven Cancers (Business Wire)
Jan-07-22 07:00AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-04-22 04:05PM	Verastem Oncology to Participate in Upcoming Investor Conferences (Business Wire)
Nov-23-21 08:53AM	Mirati (MRTX), Verastem to Study Cancer Drugs for NSCLC (Zacks)
Nov-22-21 07:30AM	Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer (PR Newswire)
Nov-15-21 06:01AM	10 Best Biotech Stocks to Buy According to Mark Lamperts Biotechnology Value Fund (Insider Monkey)
Nov-14-21 08:53AM	10 Best Biotech Stocks Under $5 (Insider Monkey)
Nov-11-21 07:00AM	Verastem Oncology to Present at the Jefferies London Healthcare Conference (Business Wire) +10.57%
Nov-04-21 04:05PM	Verastem Oncology Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress (Business Wire)
09:25AM	11 Best Long-Term Stocks To Buy Now (Insider Monkey)
Oct-26-21 07:00AM	Verastem Oncology Appoints Michelle Robertson to Board of Directors (Business Wire)

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Calkins Daniel	Chief Financial Officer	Apr 05 '24	Sale	10.87	6	65	8,535	Apr 08 04:30 PM
Calkins Daniel	Chief Financial Officer	Mar 25 '24	Sale	12.02	25	300	8,541	Mar 27 04:30 PM
Calkins Daniel	Chief Financial Officer	Mar 20 '24	Sale	11.07	55	609	8,566	Mar 21 04:31 PM
Stuglik Brian M	Director	Mar 19 '24	Sale	10.38	273	2,834	89,640	Mar 20 05:32 PM
Paterson Dan	President and CEO	Mar 19 '24	Sale	10.38	182	1,889	86,490	Mar 20 05:34 PM
Gagnon Robert E.	Director	Mar 19 '24	Sale	10.38	130	1,349	27,391	Mar 20 05:36 PM
Stuglik Brian M	Director	Mar 18 '24	Sale	10.71	537	5,751	89,913	Mar 20 05:32 PM
Gagnon Robert E.	Director	Mar 18 '24	Sale	10.71	283	3,031	27,521	Mar 20 05:36 PM
Paterson Dan	President and CEO	Mar 18 '24	Sale	10.71	244	2,613	86,672	Mar 20 05:34 PM
Gagnon Robert E.	Director	Feb 06 '24	Sale	13.70	9,204	126,095	27,804	Feb 07 04:00 PM
Gagnon Robert E.	Director	Jan 12 '24	Sale	10.95	9,204	100,784	37,008	Jan 17 04:00 PM
Calkins Daniel	Chief Financial Officer	Jan 05 '24	Sale	8.50	6	51	8,621	Jan 09 04:03 PM
Calkins Daniel	Chief Financial Officer	Dec 26 '23	Sale	8.08	25	202	8,350	Dec 28 04:04 PM
Calkins Daniel	Chief Financial Officer	Dec 20 '23	Sale	7.93	57	452	8,375	Dec 21 04:01 PM
Stuglik Brian M	Director	Dec 19 '23	Sale	7.73	274	2,118	90,450	Dec 20 04:00 PM
Paterson Dan	President and CEO	Dec 19 '23	Sale	7.73	183	1,415	86,916	Dec 20 04:01 PM
Gagnon Robert E.	Director	Dec 19 '23	Sale	7.73	130	1,005	46,212	Dec 20 04:03 PM
Stuglik Brian M	Director	Dec 18 '23	Sale	7.64	487	3,721	90,724	Dec 20 04:00 PM
Gagnon Robert E.	Director	Dec 18 '23	Sale	7.64	284	2,170	46,342	Dec 20 04:03 PM
Paterson Dan	President and CEO	Dec 18 '23	Sale	7.64	244	1,864	87,099	Dec 20 04:01 PM
Calkins Daniel	Vice President of Finance	Oct 05 '23	Sale	7.30	5	36	8,432	Oct 10 04:31 PM
Calkins Daniel	Vice President of Finance	Sep 25 '23	Sale	9.40	25	235	8,437	Sep 25 04:46 PM
Calkins Daniel	Vice President of Finance	Sep 21 '23	Sale	9.31	232	2,160	8,462	Sep 25 04:46 PM
Stuglik Brian M	Director	Sep 19 '23	Sale	9.84	274	2,696	91,211	Sep 20 04:15 PM
Paterson Dan	President and CEO	Sep 19 '23	Sale	9.84	183	1,801	87,343	Sep 20 04:15 PM
Gagnon Robert E.	Director	Sep 19 '23	Sale	9.84	130	1,279	46,626	Sep 20 04:15 PM
Stuglik Brian M	Director	Sep 18 '23	Sale	9.91	478	4,737	91,485	Sep 20 04:15 PM
Gagnon Robert E.	Director	Sep 18 '23	Sale	9.91	278	2,755	46,756	Sep 20 04:15 PM
Paterson Dan	President and CEO	Sep 18 '23	Sale	9.91	240	2,378	87,526	Sep 20 04:15 PM
Calkins Daniel	Vice President of Finance	Jul 06 '23	Sale	8.02	5	40	8,694	Jul 10 04:05 PM
Calkins Daniel	Vice President of Finance	Jun 26 '23	Sale	8.17	26	212	8,422	Jun 28 04:11 PM
Stuglik Brian M	Chief Executive Officer	Jun 20 '23	Sale	10.30	275	2,832	91,963	Jun 21 04:23 PM
Paterson Dan	President and COO	Jun 20 '23	Sale	10.30	183	1,885	37,766	Jun 21 04:25 PM
Gagnon Robert E.	Director	Jun 20 '23	Sale	10.30	130	1,339	47,034	Jun 21 04:24 PM
Stuglik Brian M	Chief Executive Officer	Jun 16 '23	Sale	9.92	487	4,831	92,238	Jun 21 04:23 PM
Gagnon Robert E.	Director	Jun 16 '23	Sale	9.92	283	2,807	47,164	Jun 21 04:24 PM
Paterson Dan	President and COO	Jun 16 '23	Sale	9.92	244	2,420	37,949	Jun 21 04:25 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

SGMO

Sangamo Therapeutics Inc

VSTM

Verastem Inc

Upgrade your FINVIZ experience